Size and duration of zidovudine benefit in 1003 HIV-infected patients: US Army, Navy, and Air Force natural history data.
Gardner-LI; Harrison-SH; Hendrix-CW; Blatt-SP; Wagner-KF; Chung-RCY; Harris-RW; Cohn-DL; Burke-DS; Mayers-DL
J Acquir Immune Defic Syndr Human Retrovirol 1998 Apr; 17(4):345-353
Objectives: the study's objectives were to determine the size and duration of benefits of early versus delayed versus late treatment with zidovudine (ZDV) on disease progression and mortality in HIV-infected patients, and whether patients rapidly progressing before ZDV treatment had a different outcome from those not rapidly progressing before ZDV. Design: the design was an inception cohort of 1003 HIV-infected patients. One hundred and seventy-four of the 1003 patients were treated before CD4 counts fell to 1400 x 10(9)/L, ("early treatment"); 183 of 1003 patients were treated after CD4 counts fell to <400 x 10(9)/L but before clinical disease developed ("delayed treatment"); and 646 of the 1003 patients had either been treated after clinical disease developed or had not been treated at all by the end of follow-up ("late treatment"). Outcomes were progression to clinical HIV disease and mortality. Results: the relative risk (RR) of progression for early versus delayed treatment was 0.58 (p < .03), and durability of ZDV benefits on progression was estimated at no more than 2.0 years; however, this estimate had wide confidence intervals. The RR of progression for delayed versus late treatment was 0.54 p < .0001, and durability of ZDV benefits was estimated at 1.74 years; this estimate had narrow confidence intervals. Survival was better for the early versus delayed treatment (RR = 0.55), but this difference was not statistically significant. In the subgroup of patients with more rapid CD4 decline prior to ZDV therapy, significant benefits on progression were observed for early versus delayed ZDV therapy (RR = 0.42, p = .02) and delayed versus late ZDV therapy (RR = 0.51; p = .0004). Duration of benefit was estimated to be 4.5 years (early versus delayed) and 1.7 years (delayed versus late). For patients with less rapid pre-ZDV decline in CD4 levels, a significant progression benefit was observed for delayed versus late therapy (RR = 0.50; p = .02). Duration of benefit in this subgroup was estimated to be 1.8 years. No significant benefit was found for early versus delayed treatment (RR = 1.12) in the less rapid pre-ZDV CD4 cell decline subgroup. Conclusions: early treatment compared with delayed treatment was associated with a sizable reduction in HIV progression, but the duration of benefits was estimated to last only about 2 years. Delayed treatment compared with late treatment with ZDV was associated with substantial reduction of progression, but this reduction was also clearly limited in duration. Benefits on progression and mortality for the early treatment group were heavily dependent on the pre-ZDV CD4 slope. In the subgroup of patients with the most rapid pre-ZDV CD4 cell declines, the duration of benefit was much longer, possibly as long as 4 years.
Military-personnel; HIV; Clinical-chemistry; Clinical-diagnosis; Clinical-pathology; Clinical-symptoms; Clinical-tests; Treatment; Statistical-analysis; Risk-factors; Cell-biology; Cell-damage; Cell-function; Cell-transformation; Cellular-function; Biochemistry; Biological-effects; Biological-factors
LI Gardner, NIOSH, DSR, Anal & Field Evaluat Branch, 1095 Willowdale Rd, Morgantown, WV 26505
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology